Search results
13 lis 2020 · In 2015, the approval for arsenic-containing drugs has been withdrawn (FDA 2015). Like other bacteria, Campylobacter has developed various resistance mechanisms, such as antibiotic-modifying enzymes, mutations of the molecular targets, and induction of efflux pumps (Table 2 ) (Iovine et al. 2013 ).
1 wrz 2021 · The XDR Campylobacter infections led to serious illness for some human patients. •. Outbreak strain was resistant to all recommended treatment agents, including macrolides and fluoroquinolones. •. The XDR profile made management of critically-ill patients a challenge. •.
6 wrz 2023 · Issues related to clinical manifestations, diagnosis, and treatment of Campylobacter infection will be reviewed here. Issues related to microbiology, pathogenesis, and epidemiology of Campylobacter infection are discussed separately, as are issues related to less-common Campylobacter species.
When an illness due to an outbreak of antimicrobial-resistant Campylobacter didn't respond to first-line defense antibiotics, researchers in the FDA’s Center for Veterinary Medicine (CVM)...
20 lip 2017 · Ciprofloxacin-resistant campylobacteriosis increased rapidly after the approval of fluoroquinolones for use in poultry and has been shown to be associated with poultry consumption, findings that contributed to the withdrawal of the approval for poultry by the FDA .
The "One World-One Health" perspective is completed by clinical aspects and molecular concepts of human campylobacteriosis offering innovative treatment options supported by novel murine infection models that are based on the essential role of innate immune activation by bacterial endotoxins.
10 sty 2023 · The New Drug Therapy Approvals report summarizes CDER’s 2022 approvals and spotlights examples of notable treatments. FDA’s Center for Biologics Evaluation and Research (CBER) also approves...
